HSBC Holdings’s Neuropace NPCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-26,033
Closed -$420K – 3097
2026
Q2
$420K Sell
26,033
-3,715
-12% -$59.8K ﹤0.01% 2367
2026
Q1
$381K Sell
29,748
-7,899
-21% -$119K ﹤0.01% 2341
2025
Q4
$579K Sell
37,647
-16,907
-31% -$226K ﹤0.01% 2240
2025
Q3
$565K Sell
54,554
-4,694
-8% -$44.3K ﹤0.01% 2042
2025
Q2
$661K Buy
+59,248
New +$741K ﹤0.01% 2003

Other funds holding NPCE

HSBC Holdings's NPCE Position: Q3 2026 in Review

HSBC Holdings sold out of Neuropace (NPCE) in Q3 2026, closing a stake of 26,033 shares — an estimated $420K sold.

HSBC Holdings first reported a position in NPCE in Q2 2025 and held it in 5 quarters. The position peaked at $661K in Q2 2025. 105 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.

  • HSBC Holdings reported no remaining Neuropace position as of Q3 2026 after selling out during the quarter.
  • HSBC Holdings sold 26,033 Neuropace shares in Q3 2026, an estimated $420K.
  • HSBC Holdings first reported a position in Neuropace in Q2 2025 and held it in 5 quarters.
  • HSBC Holdings's Neuropace position peaked at $661K in Q2 2025.
  • 105 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.

Based on HSBC Holdings's 13F filing for Q3 2026, filed 16 Nov 2026.